“I don't see really any meaningful changes in the patterns that we're expecting.”

In context

“e large biopharma end market, could you maybe talk about any changes in order behavior or patterns where there's been a pull forward of inventories just to get ahead of tariffs? And if you haven't seen that yet, do you expect that to happen? And how do you work with your customers to ensure not a significant amount of supply chain disruption in that event? Marc Casper: Yeah. So, Matt, it's a great question. And thanks for it. Given how short the announcement implementation of the tariffs, I don't really believe customers had any opportunity to pull forward. Right? It would have been we didn't see something, like, funky in the first quarter in terms of some bolus of things happening later in the quarter. We sort of got out of the normal process. And, you know, the tariffs are in effect. So I don't see really any meaningful changes in the patterns that we're expecting. And so, hopefully, that's helpful. Matt Sykes: Great. And then just for my follow-up, when you talk about manufacturing flexibility and the ability to mitigate, could you maybe at a high level just kind of talk about how flexible different types of products are? Meaning, like, is it easier to flex an instrument manufacturing facility versus, say, consumables and reagents? And how do you think about sort of the order of priorities in terms of flexing in manufacturing? I just think we all wanna get a sense for timing of truly how flexible you can be given the diverse set of products that you offer. Marc Casper: Yeah. Matt, when you think about what we've said in that guide and how fast we're able to mobilize, you can see the short time duration it takes to actually get the full impact of th”